UY32560A - Inmunoconjugados de antimesotelina y usos de los mismos - Google Patents

Inmunoconjugados de antimesotelina y usos de los mismos

Info

Publication number
UY32560A
UY32560A UY0001032560A UY32560A UY32560A UY 32560 A UY32560 A UY 32560A UY 0001032560 A UY0001032560 A UY 0001032560A UY 32560 A UY32560 A UY 32560A UY 32560 A UY32560 A UY 32560A
Authority
UY
Uruguay
Prior art keywords
antibodies
immunoconjugates
binding regions
mesothelin
antigen
Prior art date
Application number
UY0001032560A
Other languages
English (en)
Inventor
Dr Antje Kahnert
Kerstin Berhoerster
Dr Iring Heisler
Dr Charlotte Kopitz
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of UY32560A publication Critical patent/UY32560A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Abstract

Se proporciona inmonoconjugados compuestos por anticuerpos, por ejemplo anticuerpos monoclonales, o fragmentos de anticuerpos, que se unen a mesotelina,que están conjugados con agentes citotóxicos, por ejemplo maitansina, o sus derivados, y/o se co-administran o formulan con uno o más agentes anticancerosos adicionales. Los inmunoconjugados pueden usarse en procedimientos mencionados para tratar y/o diagnosticar y/o monitorizar cánceres, por ejemplo regiones de unión al antígeno recombinantes de tumores sólidos y anticuerpos y fragmentos funcionales que contienen dichas regiones de unión al antígeno que son específicas del polipéptido de mesotelina de 40 kDa anclado a membrana, que se sobreexpresa en varios tumores.
UY0001032560A 2009-04-29 2010-04-13 Inmunoconjugados de antimesotelina y usos de los mismos UY32560A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09005909 2009-04-29

Publications (1)

Publication Number Publication Date
UY32560A true UY32560A (es) 2010-11-30

Family

ID=42332769

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032560A UY32560A (es) 2009-04-29 2010-04-13 Inmunoconjugados de antimesotelina y usos de los mismos

Country Status (42)

Country Link
US (5) US9084829B2 (es)
EP (2) EP2424569B1 (es)
JP (3) JP5616433B2 (es)
KR (1) KR101681795B1 (es)
CN (2) CN106177984B (es)
AR (1) AR076284A1 (es)
AU (1) AU2010243942B2 (es)
BR (1) BRPI1014637B1 (es)
CA (1) CA2760114C (es)
CL (1) CL2011002681A1 (es)
CO (1) CO6450601A2 (es)
CR (1) CR20110566A (es)
CU (1) CU23929B1 (es)
CY (2) CY1119738T1 (es)
DK (2) DK2424569T3 (es)
DO (1) DOP2011000331A (es)
EC (1) ECSP11011423A (es)
ES (2) ES2790732T3 (es)
GT (1) GT201100269A (es)
HK (1) HK1170671A1 (es)
HN (1) HN2011002834A (es)
HR (2) HRP20180015T1 (es)
HU (2) HUE049795T2 (es)
IL (1) IL215769A (es)
JO (1) JO3486B1 (es)
LT (2) LT3292874T (es)
MA (1) MA33229B1 (es)
MX (1) MX2011011365A (es)
MY (1) MY158624A (es)
NO (1) NO2424569T3 (es)
NZ (1) NZ596013A (es)
PE (1) PE20120556A1 (es)
PL (2) PL3292874T3 (es)
PT (2) PT2424569T (es)
SG (1) SG175254A1 (es)
SI (2) SI3292874T1 (es)
TN (1) TN2011000547A1 (es)
TW (2) TW201529084A (es)
UA (2) UA116874C2 (es)
UY (1) UY32560A (es)
WO (1) WO2010124797A1 (es)
ZA (1) ZA201107757B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32560A (es) * 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
MX345519B (es) 2010-12-20 2017-02-01 Genentech Inc Anticuerpos anti-mesotelina e inmunoconjugados.
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
ME03353B (me) 2011-03-29 2019-10-20 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
WO2014004549A2 (en) * 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
EP3327037B1 (en) 2012-08-21 2019-10-09 The U.S.A. as represented by the Secretary, Department of Health and Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
WO2014043523A1 (en) * 2012-09-14 2014-03-20 The Johns Hopkins University Compositions and methods for rendering tumor cells susceptible to cd8+ t cell-mediated killing
CA2885761C (en) * 2012-09-27 2021-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
NZ707091A (en) 2012-10-04 2018-12-21 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
DK3060256T3 (da) * 2013-10-25 2019-07-29 Bayer Pharma AG Hidtil ukendt stabil formulering
TWI541022B (zh) * 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
US20150374845A1 (en) * 2014-06-27 2015-12-31 Oregon Health & Science University Compounds that bind dystroglycan and uses thereof
AU2015308618B2 (en) * 2014-08-29 2021-05-20 Corium Pharma Solutions, Inc. Microstructure array for delivery of active agents
MA40934A (fr) 2014-11-19 2017-09-27 Immunogen Inc Procédé de préparation de conjugués agent de liaison cellulaire-agent cytotoxique
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
AU2016312015A1 (en) * 2015-08-21 2018-04-12 Crage Medical Co., Limited Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
CN108601848A (zh) 2016-02-05 2018-09-28 伊缪诺金公司 用于制备细胞结合剂-细胞毒性剂缀合物的有效方法
WO2018048975A1 (en) 2016-09-09 2018-03-15 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
KR101966362B1 (ko) 2017-10-20 2019-04-05 주식회사 녹십자 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
CN110507824A (zh) * 2018-05-21 2019-11-29 荣昌生物制药（烟台）有限公司 一种抗间皮素抗体及其抗体药物缀合物
KR20210022004A (ko) * 2018-06-18 2021-03-02 안위타 바이오사이언시스, 인코포레이티드 항-메소텔린 작제물 및 이의 용도
KR20210042120A (ko) 2018-08-06 2021-04-16 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트와 튜불린 저해제의 조합
WO2020234114A1 (en) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft A novel stable high concentration formulation for anetumab ravtansine
CN111793131A (zh) * 2020-05-11 2020-10-20 廊坊天光生物技术有限公司 一种用于检测血清中pf4含量的抗体对及其用途
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
EP4222167A1 (en) 2020-09-30 2023-08-09 Nobell Foods, Inc. Recombinant milk proteins and food compositions comprising the same
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
JP2024503908A (ja) 2021-01-22 2024-01-29 バイエル アクチェンゲゼルシャフト Ｌｒｒｃ１５抗体およびそのコンジュゲート
KR20230121560A (ko) 2022-02-10 2023-08-18 경북대학교 산학협력단 메소세린에 결합하는 펩타이드 및 이의 용도

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1437180A (en) 1920-12-16 1922-11-28 Wahl Co Mechanical pencil
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
ES2129029T5 (es) 1990-10-05 2005-10-16 Celldex Therapeutics, Inc. Inmunoestimulacion dirigida con reactivos biespecificos.
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
US5773280A (en) 1992-03-20 1998-06-30 The Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
DE69214709T2 (de) 1991-04-26 1997-02-20 Surface Active Ltd Neue Antikörper und Verfahren zu ihrer Verwendung
US5407653A (en) 1991-06-26 1995-04-18 Brigham And Women's Hospital Evaluation of the multidrug resistance phenotype
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
EP0627940B1 (en) 1992-03-05 2003-05-07 Board of Regents, The University of Texas System Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors
JPH0699141A (ja) * 1992-09-21 1994-04-12 Kubota Corp 石抜装置
JPH06124641A (ja) * 1992-10-08 1994-05-06 Mitsubishi Electric Corp 回路遮断器
IL107366A (en) 1992-10-23 2003-03-12 Chugai Pharmaceutical Co Ltd Genes coding for megakaryocyte potentiator
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
WO1996013583A2 (en) 1994-10-20 1996-05-09 Morphosys Gesellschaft Für Proteinoptimierung Mbh Targeted hetero-association of recombinant proteins to multi-functional complexes
JPH0945957A (ja) * 1995-07-28 1997-02-14 Oki Electric Ind Co Ltd 端面発光型ｌｅｄアレイの製造方法及びその検査方法
JP3724015B2 (ja) * 1995-08-08 2005-12-07 コベルコ建機株式会社 パイロット切換弁の応答性可変装置
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
US7375183B1 (en) * 1996-01-05 2008-05-20 The United States Of America As Represented By The Department Of Health And Human Services Mesothelin, immunogenic peptides derived therefrom, and compositions comprising mesothelin, or immunogenic peptides thereof
CA2241604C (en) 1996-01-05 2010-03-30 Ira Pastan Mesothelium antigen and methods and kits for targeting it
CA2297070A1 (en) 1997-08-01 1999-02-11 Morphosys Ag Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
AU753336B2 (en) 1997-11-10 2002-10-17 G.D. Searle & Co. Use of alkylated iminosugars to treat multidrug resistance
US6809184B1 (en) 1997-12-01 2004-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
ATE317437T1 (de) * 1997-12-01 2006-02-15 Us Gov Health & Human Serv Antikörper, sowie fv moleküle, und immunkonjugate mit hoher bindungsaffinität für mesothelin und methoden für deren verwendung
AU3007200A (en) 1999-02-26 2000-09-14 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
WO2001002588A2 (en) 1999-07-02 2001-01-11 Morphosys Ag Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
EP1990409A3 (en) 1999-07-20 2011-05-18 MorphoSys AG Bacteriophage
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
EP1233752B1 (en) 1999-11-30 2005-01-26 The Arizona Board of Regents on behalf of The University of Arizona Radiation sensitive liposomes
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US20060246060A1 (en) 2002-07-02 2006-11-02 Nesta Douglas P Novel stable formulation
KR101424624B1 (ko) 2003-05-14 2014-07-31 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
ATE420660T1 (de) 2003-08-08 2009-01-15 Amgen Fremont Inc Antikörper gegen parath-hormon (pth) und ihre verwendungen
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
NZ551180A (en) * 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
CN1993146A (zh) * 2004-06-01 2007-07-04 健泰科生物技术公司 抗体－药物偶联物和方法
AU2006213662B2 (en) * 2005-02-11 2010-08-05 Immunogen, Inc. Process for preparing stable drug conjugates
AU2006223301B2 (en) * 2005-03-10 2010-11-04 Eisai, Inc. Anti-mesothelin antibodies
US20090047211A1 (en) * 2005-05-12 2009-02-19 The Govt. Of The U.S. As Represented By The Sec. Of The Dept. Of Health And Human Services Anti-mesothelin antibodies useful for immunological assays
ES2527428T3 (es) 2005-05-18 2015-01-23 Morphosys Ag Anticuerpos anti-GM-CSF y usos de los mismos
CN101282993A (zh) 2005-06-02 2008-10-08 阿斯利康公司 针对cd20的抗体和其用途
EP1906948A4 (en) * 2005-07-18 2010-03-17 Bipar Sciences Inc TREATMENT OF CANCER
NZ623901A (en) 2005-08-03 2015-10-30 Immunogen Inc Immunoconjugate formulations
SI1948180T1 (sl) * 2005-11-11 2013-06-28 Boehringer Ingelheim International Gmbh Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje
BRPI0618893A2 (pt) 2005-11-22 2011-09-13 Wyeth Corp formulações de proteìna de fusão de imunoglobulina
EP1854478A1 (en) 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
US8128926B2 (en) * 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
CN101951946B (zh) 2007-10-01 2014-12-10 百时美施贵宝公司 结合间皮素的人抗体及其应用
US9023351B2 (en) * 2007-11-26 2015-05-05 Bayer Intellectual Property Gmbh Anti-mesothelin antibodies and uses thereof
US8236319B2 (en) * 2008-04-30 2012-08-07 Immunogen, Inc. Cross-linkers and their uses
US20090298088A1 (en) * 2008-05-30 2009-12-03 Belyaev Alexander S Cleavable catalytic binding and detection system
MX2010013833A (es) * 2008-06-16 2011-02-15 Immunogen Inc Nuevos efectos sinergisticos.
EA027575B1 (ru) * 2008-08-05 2017-08-31 Новартис Аг Антитело или его антигенсвязывающий фрагмент, связывающий человеческий белок с5, содержащая их композиция, нуклеиновая кислота, кодирующая антитело или его антигенсвязывающий фрагмент, содержащие эту кислоту вектор и клетка-хозяин и применение антитела или его антигенсвязывающего фрагмента
CN102413839A (zh) 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
EP2411416A1 (en) * 2009-03-24 2012-02-01 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Anti-mesothelin antibodies
UY32560A (es) * 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
ES2726945T3 (es) * 2009-06-03 2019-10-10 Immunogen Inc Métodos de conjugación
WO2012143499A2 (de) 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Neue binder-wirkstoff konjugate (adcs) und ihre verwendung
DK3060256T3 (da) 2013-10-25 2019-07-29 Bayer Pharma AG Hidtil ukendt stabil formulering

Also Published As

Publication number Publication date
CY1123165T1 (el) 2021-10-29
BRPI1014637B1 (pt) 2021-08-24
CU23929B1 (es) 2013-07-31
AR076284A1 (es) 2011-06-01
LT3292874T (lt) 2020-06-10
NO2424569T3 (es) 2018-03-17
DK3292874T3 (da) 2020-06-02
JP6395783B2 (ja) 2018-09-26
US20200377614A1 (en) 2020-12-03
WO2010124797A8 (en) 2011-12-08
CL2011002681A1 (es) 2012-07-13
ES2790732T3 (es) 2020-10-29
UA106492C2 (uk) 2014-09-10
HK1170671A1 (zh) 2013-03-08
EP2424569B1 (en) 2017-10-18
KR101681795B1 (ko) 2016-12-01
US10781263B2 (en) 2020-09-22
US10647779B2 (en) 2020-05-12
JP5616433B2 (ja) 2014-10-29
NZ596013A (en) 2013-11-29
EP2424569A1 (en) 2012-03-07
KR20120031265A (ko) 2012-04-02
TN2011000547A1 (en) 2013-05-24
IL215769A (en) 2016-12-29
CA2760114C (en) 2017-11-21
AU2010243942A8 (en) 2012-06-07
TW201105351A (en) 2011-02-16
AU2010243942B2 (en) 2015-01-29
DOP2011000331A (es) 2011-11-15
PL3292874T3 (pl) 2020-10-19
US20150322160A1 (en) 2015-11-12
CN106177984A (zh) 2016-12-07
JP2017039735A (ja) 2017-02-23
JO3486B1 (ar) 2020-07-05
HUE049795T2 (hu) 2020-10-28
US20180201690A1 (en) 2018-07-19
RU2011148220A (ru) 2013-06-10
TWI472343B (zh) 2015-02-11
EP3292874B1 (en) 2020-04-08
EP3292874A1 (en) 2018-03-14
HRP20180015T1 (hr) 2018-02-09
PL2424569T3 (pl) 2018-03-30
HUE037853T2 (hu) 2018-09-28
WO2010124797A1 (en) 2010-11-04
CN102458477A (zh) 2012-05-16
PE20120556A1 (es) 2012-05-09
MX2011011365A (es) 2012-09-28
GT201100269A (es) 2013-08-21
US9084829B2 (en) 2015-07-21
UA116874C2 (uk) 2018-05-25
TW201529084A (zh) 2015-08-01
US20120189644A1 (en) 2012-07-26
SI3292874T1 (sl) 2020-07-31
MY158624A (en) 2016-10-31
AU2010243942A1 (en) 2011-11-10
CU20110200A7 (es) 2012-06-21
SI2424569T1 (en) 2018-02-28
BRPI1014637A2 (pt) 2019-04-16
DK2424569T3 (en) 2018-01-15
HN2011002834A (es) 2013-10-28
CO6450601A2 (es) 2012-05-31
IL215769A0 (en) 2012-01-31
MA33229B1 (fr) 2012-04-02
PT2424569T (pt) 2018-01-11
CR20110566A (es) 2012-02-20
PT3292874T (pt) 2020-05-15
HRP20200884T1 (hr) 2020-09-04
ES2655273T3 (es) 2018-02-19
JP2015042174A (ja) 2015-03-05
ECSP11011423A (es) 2011-11-30
ZA201107757B (en) 2012-12-27
SG175254A1 (en) 2011-11-28
JP2012525342A (ja) 2012-10-22
US20170327589A1 (en) 2017-11-16
CY1119738T1 (el) 2018-06-27
CN106177984B (zh) 2019-12-24
CA2760114A1 (en) 2010-11-04
CN102458477B (zh) 2016-08-24
LT2424569T (lt) 2018-02-12

Similar Documents

Publication Publication Date Title
UY32560A (es) Inmunoconjugados de antimesotelina y usos de los mismos
PH12018501554A1 (en) Ror1 antibody compositions and related methods
CO2017010495A2 (es) Anticuerpos que se unen a bcma y/o cd3
CL2017001580A1 (es) Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped.
ECSP19072235A (es) Anticuerpos anti-ILT4 y fragmentos de unión a antígeno
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
CL2019003050A1 (es) Conjugados de anticuerpos que comprenden agonista del receptor de tipo toll y terapias de combinación.
BR112017019978A2 (pt) anticorpo ou um fragmento de ligação com antígeno, conjugado, receptor de antígeno, cadeia, conjugado de cadeia, proteína de fusão, célula t, polinucleotídeo, vetor, célula ex vivo, método para produzir uma cadeia, método para produzir um anticorpo, composição farmacêutica, método para tratamento de câncer, glicopeptídeo, método para gerar um anticorpo
BR112018007296A2 (pt) conjugados de anticorpo compreendendo agonista de receptor tipo toll
MD3313884T2 (ro) Anticorpi anti-CD123 şi conjugaţi şi derivaţi ai acestora
CO2019013654A2 (es) Receptores de antígenos quiméricos que se dirigen a flt3
CL2012000806A1 (es) Anticuerpo anti-guanililo ciclasa c (gcc); inmunoconjugado de dicho anticuerpo; celula, vector y metodo de produccion; composicion que comprende el anticuerpo, uso del anticuerpo o composicion para preparar un medicamento para tratar cancer, particularmente del sistema gastrointestinal.
PE20090245A1 (es) Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
EA201791050A1 (ru) Конъюгаты антител и лекарственных средств
AR081750A1 (es) Anticuerpos anti-cd40
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
EA201991005A1 (ru) Антитела и полипептиды, направленные против cd127
MX2020004381A (es) Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos.
PE20212212A1 (es) Anticuerpos anti-egfrviii y fragmentos de union a antigeno de los mismos
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы
CO2022007924A2 (es) Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso
CL2018001238A1 (es) Moléculas de unión específicas para asct2 y usos de las mismas
AR081321A1 (es) N-cadherina: un blanco para el diagnostico y la terapia del cancer
BR112015031950A2 (pt) métodos para tratamento de câncer de ovário
AR106658A1 (es) Moléculas de unión específicas de asct2 y sus usos